Capricor Therapeutics (CAPR) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights
August 13, 2015 4:05 PM EDTLOS ANGELES, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided a business and financial update for the second quarter ended June 30, 2015.
Second Quarter and Recent Operational Highlights
Received FDA clearance for the HOPE-DUCHENNE Phase I/II trial of cardiosphere derived cell therapy, CAP-1002, for the treatment of Duchenne muscular dystrophy... MoreCapricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights
August 13, 2015 4:05 PM EDTLOS ANGELES, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided a business and financial update for the second quarter ended June 30, 2015.
Second Quarter and Recent Operational Highlights
Received FDA clearance for the HOPE-DUCHENNE Phase I/II trial of cardiosphere derived cell therapy, CAP-1002, for the treatment of Duchenne muscular dystrophy... More